$6.98
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 93 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, and Tacilia (omeprazole, amoxicillin and rifabutin) an oral capsule.
Country

US

CEO

Mr. A. Kazimi

IPO date

2009

Employees

93

ISIN

US2307701092

Key stats

Open

$6.85

Volume

50.29K

Market cap

$103.23M

Prev. close

$6.98

Impl / hst vl

-

Open interest

$0.00

$6.31

Day’s Range

$7.07

$2.69

52W Range

$9.28

Valuation

27
Valuation score
Overvalued
P/E
-
P/S
3.36
P/B
6.02
Current ratio
0.96
Debt / Equity
-0.22
ROE
-47.84%
Gross margin
-
Income growth
30.00%
FCF growth
-61.40

Jul

31

Dividends

The last payment date was Jul 31, 2026

Div. per Share

$1.50

Div. Yield

21.77%

Payout Ratio

-

Div. Growth YoY

-

Analysts estimates

Consensus rating
Hold

The average rating from top 3 analysts indicates that stock may significantly underperform the market

Str. Sell
Sell
Hold
Buy
Str. Buy

Earnings

Q2 ‘26 revenue
$166.50K
Q2 ‘26 net income
-$4.28M
Revenue
Net income
Previous EPS
-$0.20
Estimate EPS
$0.00
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply